Understanding how OCT2 functionality influences both insulin sensitivity and beta cell function could lead to more personalized treatment approaches, improving outcomes for individuals with T2DM, especially those using metformin as a primary therapeutic agent. This evidence concerns the gene INS and type 2 diabetes mellitus.